As a part of the ongoing and complicated process of trying to appreciate and give meaning to the various ways wheezing can develop across the life cycle, Louis Bont and team have published their research into the association between RSV and susceptibility to all cause wheeze. Giving palivizumab to all “late” (32-36 wk gestation) preterm infants resulted in prevention of 61% of all causes of wheeze in infants. In his talk indicated that his cohort of patients is 6y old and they are collecting parameters which he imagines will be published in another few years.
In his talk he acknowledged that there are likely to be a number of pathways multiple asthma phenotypes (or even “endotypes”). Fortunately, the discussion remained very contained, but in my mind I continue to struggle to properly organise the relationship between wheezing illnesses.